IRL-1620 Injection Shown to Boost Brain Recovery Process in Alzheimer's
At the 14th International Conference on Endothelin: Physiology, Pathophysiology, and Therapeutics, researchers presented data on treatment of Alzheimer's dementia in rats with IRL-1620, a chemical that binds to endothelin B receptors.
Previous studies had shown endothelin B receptors were important in brain development. Researchers set out to stimulate endothelin B receptors by intravenous (IV) injection of IRL-1620 to prevent and repair damage to the brain. When they administered IRL-1620 in rats with Alzheimer's dementia, they saw an improvement in memory deficit by 50–60% and a reduction in oxidative stress by 45–50%. Treatment with IRL-1620 boosted certain recovery processes within the damaged brain, which resulted in more new blood vessels and neuronal cells.
This was the first study to indicate that selective stimulation of the endothelin B receptors by IV IRL-1620 improved memory, reduced oxidative stress, and enhanced neurovascular remodeling in animal mode of Alzheimer's dementia, study authors concluded.
For more information visit The-APS.org.